NHS England has today deferred a decision on Vimizim - the drug required by six-year-old Morquio syndrome patient Sam Brown from Otley - by a further 12-16 weeks.
Adam Fowler reports:
After a wait of more than six months, NHS England it will make its final decision on funding after after NICE, the National Institute for Health and Care Excellence has concluded its report into the drug.
NICE has said that doubts exist about the benefits and cost of this treatment in its recent draft guidance, and is therefore “minded not to recommend” the treatment for patients with Morquio A Syndrome. The manufacturer now has the opportunity to present additional evidence to NICE to address these concerns. If NICE ultimately does recommend the NHS funds this treatment then NHS England will do so. NHS England believes the manufacturer has an ethical duty to continue to support those patients it enrolled in clinical trials of elosulfase alfa whilst the NICE process is still ongoing.
Sam Brown received his last free round of treatment last week.
BioMarin, the company which provides Sam's treatment said it was "disappointed" by NHS England's decision.
BioMarin is disappointed by NHS England’s decision not to provide interim funding for Vimizim. Vimizim is the only enzyme replacement therapy for people with Morquio A syndrome, a rare genetic condition that is progressively degenerative and life limiting. BioMarin continues to work closely with all stakeholders to ensure that a long term funding solution for Vimizim is found for all patients with Morquio A syndrome, so that they are able to access this treatment in England.
More top news
Will the cold burst continue? Kerrie Gosney has the latest forecast.
A woman from Leeds says more needs to be done to stop people from falling into open water, three years after her father drowned.
Up to 600 homes in North Yorkshire have been left without gas after a main pipe "collapsed" during routine repair work.